Overview

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2029-01-23

Target enrollment:

Participant gender:

Summary

To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with ICI-refractory melanoma who are receiving the combination of ipilimumab and nivolumab as part of their standard care.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Ipilimumab
Nivolumab